IRC
GSK icon

Investors Research Corp’s GSK GSK Stock Holding History

Investors Research Corp’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Sell
14,952
-576
-4% -$30.5K 0.14% 125
2026
Q1 		$857K Sell
15,528
-2,480
-14% -$134K 0.16% 116
2025
Q4 		$883K Sell
18,008
-620
-3% -$28.9K 0.16% 120
2025
Q3 		$804K Hold
18,628
– – 0.15% 137
2025
Q2 		$715K Hold
18,628
– – 0.14% 156
2025
Q1 		$722K Hold
18,628
– – 0.16% 139
2024
Q4 		$630K Sell
18,628
-432
-2% -$15.6K 0.14% 169
2024
Q3 		$779K Buy
19,060
+60
+0.3% +$2.46K 0.17% 144
2024
Q2 		$732K Hold
19,000
– – 0.17% 150
2024
Q1 		$815K Buy
19,000
+1,940
+11% +$80K 0.19% 134
2023
Q4 		$632K Sell
17,060
-2,440
-13% -$87.6K 0.15% 175
2023
Q3 		$707K Hold
19,500
– – 0.18% 151
2023
Q2 		$695K Buy
19,500
+7,004
+56% +$251K 0.18% 155
2023
Q1 		$445K Sell
12,496
-199
-2% -$6.96K 0.12% 225
2022
Q4 		$446K Sell
12,695
-100
-0.8% -$3.33K 0.12% 222
2022
Q3 		$377K Sell
12,795
-3
-0% -$114 0.12% 221
2022
Q2 		$696K Hold
12,798
– – 0.21% 144
2022
Q1 		$697K Hold
12,798
– – 0.2% 143
2021
Q4 		$706K Hold
12,798
– – 0.21% 132
2021
Q3 		$611K Hold
12,798
– – 0.21% 157
2021
Q2 		$637K Hold
12,798
– – 0.22% 151
2021
Q1 		$571K Sell
12,798
-320
-2% -$14.5K 0.22% 161
2020
Q4 		$603K Sell
13,118
-369
-3% -$16.9K 0.24% 155
2020
Q3 		$635K Hold
13,487
– – 0.31% 99
2020
Q2 		$688K Sell
13,487
-180
-1% -$9.23K 0.35% 91
2020
Q1 		$647K Sell
13,667
-356
-3% -$19K 0.4% 60
2019
Q4 		$824K Hold
14,023
– – 0.38% 73
2019
Q3 		$748K Sell
14,023
-160
-1% -$8.23K 0.38% 76
2019
Q2 		$710K Hold
14,183
– – 0.37% 84
2019
Q1 		$741K Hold
14,183
– – 0.4% 73
2018
Q4 		$677K Hold
14,183
– – 0.47% 69
2018
Q3 		$712K Sell
14,183
-85
-0.6% -$4.32K 0.41% 85
2018
Q2 		$719K Buy
14,268
+230
+2% +$11.6K 0.42% 80
2018
Q1 		$686K Buy
14,038
+520
+4% +$24.2K 0.42% 87
2017
Q4 		$599K Buy
+13,518
New +$624K 0.37% 99

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return

Investors Research Corp's GSK Position: Q2 2026 in Review

Investors Research Corp reduced its GSK (GSK) stake by 3.7% in Q2 2026, selling an estimated $30.5K and leaving 14,952 shares worth $784K. The position accounts for 0.14% of the portfolio, ranked #125.

Investors Research Corp first reported a position in GSK in Q4 2017 and has held it in 35 quarters since. The position peaked at $883K in Q4 2025. 173 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Investors Research Corp held 14,952 shares of GSK worth $784K as of Q2 2026.
  • Investors Research Corp sold 576 GSK shares in Q2 2026, an estimated $30.5K.
  • GSK made up 0.14% of Investors Research Corp's portfolio in Q2 2026, its #125 holding.
  • Investors Research Corp first reported a position in GSK in Q4 2017 and has held it in 35 quarters since.
  • Investors Research Corp's GSK position peaked at $883K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.